Trial Profile
Phase II study of erlotinib in advanced or recurrent EGFR mutation positive Non-small cell lung cancer patients who were previously treated with intrapleural therapy for malignant pleural effusion.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2011
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Oct 2011 New trial record